Lonza’s innovative continuous flow technology and mini-monoplant approach are transforming early-phase drug development. How ...
An average drug candidate takes 10 to 15 years to progress through the development cycle. For every 5,000 compounds that ...
The two companies have been working together since 2017, and, in 2021, they agreed to collaborate on NM26, a bispecific ...
The path from a scientist’s initial idea to a new medicine that can save lives is a complex and often lengthy process. It ...
23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...
CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: ...
AZoLifeSciences on MSN1d
The Commercialization Process for Antibody TherapeuticsThe rise of antibody therapeutics is transforming drug discovery, providing highly specific treatments for complex diseases ...
ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed ...
Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor ...
The Company's full financial statements and related MD&A for the first quarter ended September 30, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback